<DOC>
	<DOC>NCT02539537</DOC>
	<brief_summary>French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma</brief_summary>
	<brief_title>A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1. Histologically or cytologically confirmed adenocarcinoma of the pancreas 2. Proven unresectability after multidisciplinary discussion involving radiologist and a surgeon 3. Locally advanced (i.e.: no metastasis or suspicion of metastasis) and unresectable tumors: for example mesenteric or portal vein involvement, or &gt; 180° encasement of the superior mesenteric artery, or celiac abutment (NCCN 2012 criteria) 4. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST 1.1 criteria 5. WHO Performance status (PS) 01 6. Age ≥18 years 7. Patient with organ function as follows: absolute neutrophil count (ANC) ≥ 1.5 x 109/L Hemoglobin ≥ 10 g/dL platelets (PTL) ≥ 75 x 109/L AST/ALT ≤ 2.5x ULN bilirubin ≤ 1.5 x ULN creatinine ≤ 2 x ULN albumin &gt; 0.75 x LLN urea ≤ 2 x ULN 8. Adequate vital functions 9. Patient of childbearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use medically acceptable methods of contraception during the study and for 4 months after the last intake of study treatment for women and for 6 months after for men. 10. Patient information and signed informed consent form 11. Public or private health insurance coverage 1. Patient treated for a cancer other than pancreatic cancer within 5 years before enrolment, with the exception of basal cell carcinoma or in situ cervical cancer 2. Patient with metastasis or with history of metastasis 3. Patient with grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e. congestive heart failure, myocardial infarction within 6 months before baseline) 4. Major comorbidity, active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes that may preclude the delivery of the treatment. 5. Preexisting neuropathy (Grade ≥ 2), Gilbert's disease or genotype UGT1A1 * 28 / * 28. 6. Pregnant woman 7. Fructose intolerance. 8. Patients currently treated by warfarine 9. Persons deprived of liberty or under guardianship. 10. Psychological condition, family, sociological or geographical situation potentially hampering compliance with the study protocol and the followup schedule.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>locally advanced pancreatic carcinoma</keyword>
	<keyword>FOLFIRINOX</keyword>
</DOC>